Cipla Company Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the competitive landscape for CIPLA, and when can generic versions of CIPLA drugs launch?
CIPLA has ninety-two approved drugs.
There are six US patents protecting CIPLA drugs. There are twenty tentative approvals on CIPLA drugs.
There are thirty patent family members on CIPLA drugs in twenty-one countries and three hundred and ninety-nine supplementary protection certificates in seventeen countries.
Summary for Cipla
International Patents: | 30 |
US Patents: | 6 |
Tradenames: | 81 |
Ingredients: | 81 |
NDAs: | 92 |
Patent Litigation for Cipla: | See patent lawsuits for Cipla |
PTAB Cases with Cipla as petitioner: | See PTAB cases with Cipla as petitioner |
Drugs and US Patents for Cipla
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cipla | LEVALBUTEROL HYDROCHLORIDE | levalbuterol hydrochloride | SOLUTION;INHALATION | 078171-003 | Dec 13, 2013 | AN | RX | No | No | See Plans and Pricing | See Plans and Pricing | ||||
Cipla Ltd | ZIDOVUDINE | zidovudine | SOLUTION;ORAL | 077981-001 | Jun 26, 2008 | AA | RX | No | No | See Plans and Pricing | See Plans and Pricing | ||||
Cipla | PREGABALIN | pregabalin | CAPSULE;ORAL | 212280-007 | Jan 10, 2020 | AB | RX | No | No | See Plans and Pricing | See Plans and Pricing | ||||
Cipla | CINACALCET HYDROCHLORIDE | cinacalcet hydrochloride | TABLET;ORAL | 208915-002 | Mar 8, 2018 | AB | RX | No | No | See Plans and Pricing | See Plans and Pricing | ||||
Cipla | NEVIRAPINE | nevirapine | TABLET;ORAL | 077956-001 | May 22, 2012 | AB | RX | No | No | See Plans and Pricing | See Plans and Pricing | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Cipla Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
China | 101868472 | See Plans and Pricing |
Eurasian Patent Organization | 201070597 | See Plans and Pricing |
European Patent Office | 3150617 | See Plans and Pricing |
Japan | 2011219498 | See Plans and Pricing |
Cyprus | 1118915 | See Plans and Pricing |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Cipla Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0785926 | 08C0041 | France | See Plans and Pricing | PRODUCT NAME: AMBRISENTAN; REGISTRATION NO/DATE: EU/1/08/451/001-004 20080421 |
0480717 | C990009 | Netherlands | See Plans and Pricing | PRODUCT NAME: MONTELUKASTUM, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER NATRII MONTELUKASTUM; NATL REGISTRATION NO/DATE: RVG 23164 AND RVG 23165 19981103; FIRST REGISTRATION: FI 12766 AND 12767 19970825 |
1411900 | 2011C/016 | Belgium | See Plans and Pricing | PRODUCT NAME: NAPROXENE ET ESOMEPRAZOLE (SOUS LA FORME D'ESOMEPRAZOLE MAGNESIUM TRIHYDRATE); AUTHORISATION NUMBER AND DATE: BE382505 20101214 |
2340828 | LUC00195 | Luxembourg | See Plans and Pricing | PRODUCT NAME: SACUBITRIL ET VALSARTAN, SOUS FORME DE COMPLEXE DE SEL DE SODIUM SACUBITRIL VALSARTAN, C'EST-A-DIRE (((S)-N-VALERYL-N-((2'-(1H-TETRAZOLE-5-YL)-BIPHENYL-4-YL)-METHYL)-VALINE) ((2R,4S)-5-BIPHENYL-4-YL-4-(3-CARBOXY-PROPIONYLAMINO)-2-METHYL-ESTER ETHYLIQUE D'ACIDE PENTANOIQUE))NA3 X H2O, DANS LEQUEL X EST 0 A 3; AUTHORISATION NUMBER AND DATE: EU/1/15/1058 20151123 |
1301519 | CR 2016 00012 | Denmark | See Plans and Pricing | PRODUCT NAME: TENOFOVIRALAFENAMID ELLER ET SALT ELLER SOLVAT DERAF, I SAERDELESHED TENOFOVIRALAFENAMIDFUMARAT; REG. NO/DATE: EU/1/15/1061/001-002 20151123 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |